CDSCO Issues Guidelines For Registration Of Medical Devices As Voluntary Registration Period Comes To An End

New Delhi : Medical devices in the Class A and B will fall under the licensing regime in a year from now, on October 1, 2022, while the Class C and D will come under the regime a year after that, according to the Central Drugs Standard Control Organisation (CDSCO).

The document was issued by the Organisation to help the industry which has come out with several related queries, many of them basic FAQs, even as the mandatory registration for Class A and B are expected to start in a few days now.

In a guidance document issued for manufacturers and importers for voluntary and mandatory registration of medical devices, the Organisation said that the registration of Class A, B, C and D devices has been kept voluntary for a period of 18 months with effect from April 1, 2020, till September 30, 2021.

Voluntary registration of Class A and B devices shall be followed by mandatory registration for 12 months after the 18 months of Voluntary registration period is over, that is up to September 30, 2022.

“From October 1, 2022 Class A & B devices will fall under licensing regime,” said the guidance document.

Voluntary registration of Class C and D devices shall be followed by mandatory registration for 24 months after 18 months’ voluntary registration period is over that is October 1, 2021 to September 30, 2023. From October 1, 2023 Class C&D devices will fall under licensing regime.

Documents required for registration of medical devices by the manufactures include the name and address of the company or firm or any other entity manufacturing the medical device along with name and address of manufacturing site of medical device; details of medical device; certificate of compliance with respect to ISO 13485 standard accredited by National Accreditation Board for Certification Bodies or International Accreditation Forum in respect of such medical device; and an undertaking duly signed by the manufacturer stating that the information furnished by the applicant is true and authentic.

Documents required for registration of medical devices by the Importers include the name of the company or firm or any other entity importing the medical device; details of medical device; specification and standards of that medical device; certificate of compliance with respect to ISO 13485 standard accredited by National Accreditation Board for Certification Bodies or International Accreditation Forum in respect of such medical device; and free sale certificate from country of origin.

The guidance document also has detailed steps the manufacturers and importers can follow to register non-notified medical devices.

  • Related Posts

    Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test

    Basel- Roche announced today that the cobas® MPX-E assay, a qualitative in-vitro test for the detection and discrimination of Human Immunodeficiency Virus (HIV 1 and 2) and Hepatitis C, B,…

    Haryana Mandates Real-Time Medicine Tracking In Govt Hospitals

    Chandigarh: In a major push to strengthen public healthcare, the Haryana Government has directed all government hospitals to maintain medicine stock records on a real-time centralised portal, ensuring transparency and…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test

    Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test

    Haryana Mandates Real-Time Medicine Tracking In Govt Hospitals

    Haryana Mandates Real-Time Medicine Tracking In Govt Hospitals

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

    Diabetic drug metformin found to act on brain

    Diabetic drug metformin found to act on brain

    Hetero debuts semaglutide generic in emerging markets

    Hetero debuts semaglutide generic in emerging markets

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial